Fig. 4
From: Evaluation of dosing strategy for pembrolizumab for oncology indications
Distribution of observed pembrolizumab AUCss, 0-6weeks: Panel a – Consistency with model predictions (Simulated values shown in gray and observed values in white). Panel b – Variation in exposures with body weight under weight-based versus fixed dosing. Box: straight middle line = median; edges = 25th and 75th percentiles; whiskers = 10th and 90th percentiles; dots = 5th and 95th percentiles. Horizontal dashed lines (------) represent the range of exposures (5th percentile of 2 mg/kg Q3W and 95th percentile of 10 mg/kg Q2W) from dose regimens demonstrated to have comparable efficacy and tolerability in melanoma and previously treated NSCLC trials. Observed data are based on Table 1. In Panel B, distribution of observed AUCss, 0-6weeks for light (≤50 kg), middle (between 50 and 90 kg) and heavy (≥90 kg) body-weight patients